International Journal of Clinical Case Reports 2024, Vol.14, No.3, 117-131 http://medscipublisher.com/index.php/ijccr 128 Ioannou G., Bohnert A., O'Hare A., Boyko E., Maciejewski M., Smith V., Bowling C., Viglianti E., Iwashyna T., Hynes D., Berry K., Green P., Fox A., Korpak A., Shahoumian T., Hickok A., Rowneki M., Wang X., and Locke E., 2022, Effectiveness of mRNA COVID-19 vaccine boosters against infection, hospitalization, and death: a target trial emulation in the omicron (B.1.1.529) variant era, Annals of Internal Medicine, 175(12): 1693-1706. https://doi.org/10.7326/M22-1856 PMid:36215715 PMCid:PMC9575390 Jackson N., Kester K., Casimiro D., Gurunathan S., and Derosa F., 2020, The promise of mRNA vaccines: a biotech and industrial perspective, NPJ Vaccines, 5: 11. https://doi.org/10.1038/s41541-020-0159-8 PMid:32047656 PMCid:PMC7000814 Kim J., Eygeris Y., Gupta M., and Sahay G., 2021, Self-assembled mRNA vaccines, Advanced Drug Delivery Reviews, 170: 83-112. https://doi.org/10.1016/j.addr.2020.12.014 PMid:33400957 PMCid:PMC7837307 Klein N., Stockwell M., Demarco M., Gaglani M., Kharbanda A., Irving S., Rao S., Grannis S., Dascomb K., Murthy K., Rowley E., Dalton A., DeSilva M., Dixon B., Natarajan K., Stenehjem E., Naleway A., Lewis N., Ong T., Patel P., Konatham D., Embí P., Reese S., Han J., Grisel N., Goddard K., Barron M., Dickerson M., Liao I., Fadel W., Yang D., Arndorfer J., Fireman B., Griggs E., Valvi N., Hallowell C., Zerbo O., Reynolds S., Ferdinands J., Wondimu M., Williams J., Bozio C., Link-Gelles R., Azziz‐Baumgartner E., Schrag S., Thompson M., and Verani J., 2022, Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 Years - VISION Network, 10 states, April 2021-January 2022, Morbidity and Mortality Weekly Report, 71: 352-358. https://doi.org/10.15585/mmwr.mm7109e3 PMid:35239634 PMCid:pmc8893336 Knezevic I., Liu M., Peden K., Zhou T., and Kang H., 2021, Development of mRNA vaccines: scientific and regulatory issues, Vaccines, 9(2): 81. https://doi.org/10.3390/vaccines9020081 PMid:33498787 PMCid:PMC7910833 Korang S., Rohden E., Veroniki A., Ong G., Ngalamika O., Siddiqui F., Juul S., Nielsen E., Feinberg J., Petersen J., Legart C., Kokogho A., Maagaard M., Klingenberg S., Thabane L., Bardach A., Ciapponi A., Thomsen A., Jakobsen J., and Gluud C., 2022, Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials, PLoS ONE, 39(17): 3845-3852. https://doi.org/10.1371/journal.pone.0260733 PMid:35061702 PMCid:PMC8782520 Liang Y., Huang L., and Liu T., 2021, Development and delivery systems of mRNA vaccines, Frontiers in Bioengineering and Biotechnology, 9: 718753. https://doi.org/10.3389/fbioe.2021.718753 PMid:34386486 PMCid:PMC8354200 Ma F., Yang J., Kang G., Sun Q., Lu P., Zhao Y., Wang Z., Luo J., and Wang Z., 2016, Comparison of the safety and immunogenicity of live attenuated and inactivated hepatitis A vaccine in healthy Chinese children aged 18 months to 16 years: results from a randomized, parallel controlled, phase IV study., Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 22(9): 811.e9-811.e15. https://doi.org/10.1016/j.cmi.2016.06.004 PMid:27345175 Maruggi G., Zhang C., Li J., Ulmer J., and Yu D., 2019, mRNA as a transformative technology for vaccine development to control infectious diseases., Molecular therapy : the journal of the American Society of Gene Therapy, 27(4): 757-772. https://doi.org/10.1016/j.ymthe.2019.01.020 PMid:30803823 PMCid:PMC6453507 Naranbhai V., García-Beltrán W., Chang C., Mairena C., Thierauf J., Kirkpatrick G., Onozato M., Cheng J., Denis K., Lam E., Kaseke C., Tano-Menka R., Yang D., Pavlovic M., Yang W., Kui A., Miller T., Astudillo M., Cahill J., Dighe A., Gregory D., Poznansky M., Gaiha G., Balazs A., and Iafrate A., 2021, Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 vaccines, The Journal of Infectious Diseases, 225: 1141-1150. https://doi.org/10.1093/infdis/jiab593 PMid:34888672 PMCid:PMC8689763 Olson S., Newhams M., Halasa N., Price A., Boom J., Sahni L., Irby K., Walker T., Schwartz S., Pannaraj P., Maddux A., Bradford T., Nofziger R., Boutselis B., Cullimore M., Mack E., Schuster J., Gertz S., Cvijanovich N., Kong M., Cameron M., Staat M., Levy E., Chatani B., Chiotos K., Zambrano L., Campbell A., Patel M., and Randolph A., 2021, Effectiveness of pfizer-BioNTech mRNA vaccination against COVID-19 hospitalization among persons aged 12-18 years-united states, june-september 2021., MMWR, Morbidity and mortality weekly report, 70(42): 1483-1488. https://doi.org/10.15585/mmwr.mm7042e1 PMid:34673751 PMCid:PMC9361838 Pardi N., Hogan M., Porter F., and Weissman D., 2018, mRNA vaccines - a new era in vaccinology, Nature Reviews Drug Discovery, 17: 261-279. https://doi.org/10.1038/nrd.2017.243 PMid:29326426 PMCid:PMC5906799
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==